Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
GTx, Inc. (Nasdaq: GTXI) today provides a Company update and reports financial results for the second quarter of 2013.
Clinical updates
GTx is evaluating enobosarm (GTx-024) 3 mg, an oral selective androgen receptor modulator, for the prevention and treatment of muscle wasting in patients with advanced non-small cell lung cancer in two pivotal Phase 3 clinical trials.
Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!
